The US Food and Drug Administration has approved spesolimab-sbzo, an interleukin -36 receptor antagonist, for the treatment of generalized pustular psoriasis in adults and in pediatric patients aged ≥ 12 years who weigh ≥ 40 kg, according to an announcement from the manufacturer., the product is an injectable antibody that blocks the IL-36 receptor, a key part of the pathway shown to be involved in the cause of GPP, which is rare and is a potentially-life-threatening disease.
Spesolimab-sbzo is currently available in 48 countries, according to the Boehringer Ingelheim release, which states that the approval makes it the firstAll material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »
Source: FoxBusiness - 🏆 458. / 53 Read more »
Source: FOXLA - 🏆 445. / 53 Read more »